相关实验视频
Updated: Jun 18, 2025

06:20
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
2.7K
洞察H3K4 KMTs在胰腺癌中驱动的机制
Kayla C LaRue-Nolan1,2, Glancis Luzeena Raja Arul3, Ashley N Sigafoos1
1Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, MN, U.S.A.
The Biochemical journal
|July 30, 2024
概括
基因组 lysine 甲基转移酶 (KMTs) 在胰腺管腺癌 (PDAC) 的发展中起着至关重要的作用. 最近的研究强调了它们作为瘤抑制剂的潜力,为这种致命的癌症提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 胰腺管腺癌 (PDAC) 是一种致命的恶性瘤,存活率较低.
- 遗传变化驱动PDAC,但针对它们的成功有限.
- 焦点正在转移到非遗传因素,包括表观遗传变化,在PDAC病原体.
研究的目的:
- 审查基因组 lysine 甲基转移酶 (KMTs) 在PDAC中的作用.
- 讨论KMTs在PDAC开发和治疗中的翻译意义.
- 探索KMTs作为瘤抑制剂在胰腺癌中的新兴作用.
主要方法:
- 在PDAC中对KMTs的文献综述.
- 对PDAC.中的表观遗传修饰,特别是H3K4me1的分析.
- 检查KMTs在基因调节和瘤进展中的功能.
主要成果:
- 在KMTs中存储H3K4me1,这是与增强元件相关的标记.
- 增强剂的失调与PDAC生长和转移有关.
- 新出现的证据表明,KMTs可能在PDAC中充当瘤抑制剂,与其在其他癌症中的作用相反.
结论:
- 在PDAC中,KMTs是表观遗传场景的关键调节者.
- 了解KMT的双重作用对于开发有效的PDAC疗法至关重要.
- 针对KMTs或它们的相关途径可能为PDAC提供新的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Spreading of Chromatin Modifications
8.2K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.2K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

